No permanent DNA edit
Suppressor tRNAs act during translation on the mRNA message rather than permanently changing the genome.
The shared molecular failure
The protein-making message
stops too early.
A nonsense mutation creates a premature termination codon. The ribosome stops before the protein is complete, and the cell may also destroy the message through nonsense-mediated decay.
The KritRNA solution
Teach the ribosome to read through the premature stop
KritRNA is developing engineered suppressor tRNAs that recognise selected premature stop codons and deliver an amino acid so translation can continue toward a full-length protein.
This is not simply a workaround for one disease. It is a programmable therapeutic strategy built around a molecular failure shared across many diseases.
From interruption to restoration
01Premature stop identified
02Suppressor tRNA designed
03Ribosome decodes the selected stop
04Translation continues
05Full-length protein is evaluated
Why suppressor tRNA is different
A distinct therapeutic logic
Suppressor tRNA combines translation-level intervention with programmable molecular design and cross-disease platform potential.
Designed for the selected stop
Candidates can be engineered around the stop codon, intended amino acid and local sequence context.
Uses the cell’s own transcript
The objective is to restore full-length protein from endogenous mRNA already produced by the cell.
A platform across diseases
Because the same molecular failure occurs in different genes, learning can compound across multiple programmes.
Therapeutic landscape
Different modalities, different biological trade-offs
KritRNA’s approach is not a copy of gene replacement, editing or small-molecule readthrough. It is a separate modality with its own strengths, risks and development requirements.
Established modality class
Gene replacement / gene therapy
Introduces a working genetic payload and can be powerful, but payload size, delivery, durability, immune response and manufacturing can vary substantially by disease.
Established modality class
Genome editing
Changes DNA at a selected locus and may offer durable correction, but requires controlled delivery, edit specificity and long-term safety assessment.
Established modality class
Small-molecule readthrough
Can promote readthrough in some contexts, but activity may vary with stop codon, sequence, dose and disease biology.
KritRNA modality
Suppressor tRNA
A programmable translation-level modality designed to decode selected premature stops and restore full-length protein without permanent genome modification.
The modality has demonstrated promise in peer-reviewed preclinical research. KritRNA’s next task is to convert that promise into rigorously designed, disease-relevant candidates and reproducible experimental evidence.
Explore the suppressor-tRNA science →